Multicenter Registry Study Of Cerebral Venous Thrombosis In China (RETAIN-CH)

Study Overview
=================
Brief Summary
-----------------
This study will investigate the epidemiology, risk factors, diagnostics, treatment, and the long-term prognosis of cerebral venous thrombosis in China.

Detailed Description
-----------------
The epidemiology, risk factors, diagnosis and treatment of Cerebral Venous Thrombosis (CVT) in China are still unclear. A retrospective hospital-based study will be conducted at fifty different hospitals across 31 provinces in China. This study will use ICD-10 to search patients diagnosed with CVT between January 1, 2018 and June 15, 2022 across 31 provinces and municipalities of 104 hospitals in China. Risk factors, clinical and radiological findings, treatment and short-term outcomes will be recorded from the hospital record system. Finally, a prospective follow-up will be conducted for all of the patients enrolled above. By combining data collected from retrospective hospital records with the new follow-up, it will be possible to better understand the epidemiology, risk factors, diagnosis, treatment and the long-term prognosis of CVT in China.

Official Title
-----------------
A Registry Study of Cerebral Venous Sinus Thrombosis in China

Conditions
-----------------
Cerebral Vein Thrombosis, Cerebral Venous Sinus Thrombosis

Participation Criteria
=================
Eligibility Criteria
-----------------
Inclusion Criteria: Cerebral venous sinus thrombosis, deep cerebral vein thrombosis and cortical vein thrombosis diagnosed by digital subtraction angiography (DSA), magnetic resonance venography (MRV), computed tomography venography (CTV) or high-resolution magnetic resonance imaging (HR-MRI). Exclusion Criteria: None of the patient, trustee or immediate family members signed the informed consent.
Sexes Eligible for Study
-----------------
All

Accepts Healthy Volunteers
-----------------
No

Study Plan
=================
How is the study designed?
-----------------
What is the study measuring?
-----------------
Primary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Favorable clinical outcome (modified Rankin score 0-1) |  | Baseline to three years | 
| All-cause mortality | A combination of death form of all causes | Baseline to three years | 

Secondary Outcome Measures

| Outcome Measure | Measure Description | Time Frame |
| --- | --- | --- |
| Recurrence of cerebral venous thrombosis | Diagnosed by DSA, MRV, CTV or HR-MRI | Baseline to three years | 
| Favorable clinical outcome (modified Rankin score 0-2) |  | Baseline to three years | 
| Headache after CVT | Headache Impact Test - 6 score | Baseline to three years | 
| Incidence of hemorrhagic complication | Extracranial hemorrhage (fall in hemoglobin of 2 gram/dl or more within 48 hours) or intracranial hemorrhage | Baseline to three years | 
| Recanalization rate of cerebral venous system |  | Baseline to three years | 
| Incidence of epilepsy |  | Baseline to three years | 
| Incidence of acute ischemic stroke |  | Baseline to three years | 
| Incidence of pulmonary embolism |  | Baseline to three years | 
| Psychological distress after CVT | Population Health Questionnaire (PHQ)-9 score | Baseline to three years | 

 Terms related to the study
=================
Keywords Provided by Centre Hospitalier Valida
-----------------
Cerebral Venous Sinus Thrombosis